新型口服抗凝药利伐沙班片在急性冠状动脉综合征中的研究  

Study on the new oral anticoagulant of rivaroxaban tablets in acute coronary syndrome

作　　者：潘培培[1] 林丽芳[1] 方建梅[1] 周浩[1] 

机构地区：[1]温州医科大学附属第一医院心内科,浙江温州325000

出　　处：《中国现代医生》2017年第21期21-24,共4页China Modern Doctor

基　　金：浙江省公益技术研究社会发展项目(2014C33166)

摘　　要：目的分析新型口服抗凝药利伐沙班片在急性冠状动脉综合征中临床应用的研究。方法选择本院心内科2015年2月~2016年11月80例急性冠状动脉综合征患者为研究对象,分为实验组和对照组,每组各40例,实验组在常规治疗基础上,加用利伐沙班2.5 mg每日2次口服进行治疗,对照组在常规治疗基础上,行低分子肝素0.4 mg每日2次腹壁皮下注射进行治疗,对比两组患者用药后的治疗效果心脑血管事件以及并发症出血事件的发生率,分析新型口服抗凝药利伐沙班片在急性冠状动脉综合征中的使用效果。结果实验组发生心绞痛发作2例,再发心肌梗死1例,心律失常2例,发生率12.5%,对照组发生心绞痛发作1例,再发心肌梗死2例,心律失常1例,发生率10.0%,两组患者用药后的心脑血管事件比较,差异无统计学意义(P>0.05)。实验组发生牙龈出血1例,鼻腔出血1例,总出血率为5.0%,对照组发生牙龈出血2例,鼻腔出血1例,总出血率为7.5%,两组患者用药后总出血率比较,差异无统计学意义(P>0.05)。结论新型口服抗凝药利伐沙班片在急性冠状动脉综合征中的应用有效、安全。同时给予加强用药宣教、病情观察及并发症出血处理,可安全有效地应用药物,有利于患者的愈合。Objective To study the clinical application of a new oral anticoagulant of tivaroxaban tablet in acute coro- nary syndrome. Methods Eighty patients with acute coronary syndromes in the Department of Cardiology in our hospital from February 2015 to November 2016 were selected as the research subjects. The patients were divided into experi- mental group and control group, with 40 patients in each group. The experimental group was further orally given 2.5 mg of rivaroxaban twice a day on the basis of conventional treatment. The control group was given abdominal subcutaneous injection of 0.4 mg of low molecular weight heparin twice a day on the basis of conventional treatment. The curative effect, cardiovascular and cerebrovaseular events and the incidence rate of complications of bleeding were compared between the two groups of patients after drug administration. The application effect of the new oral anticoagulant of rivaroxaban tablets in the treatment of acute coronary syndrome was analyzed. Results Two cases of angina pectoris, 1 case of recurrent myocardial infarction, 2 cases of arrhythmia were observed in the experimental group, and the inci- dence rate was 12.5%. 1 case of angina pectorls, 2 cases of recurrent myocardial infarction, and 1 case of arrhythmia were observed in the control group, with the incidence rate of 10.0%. There was no statistically significant difference between the two groups in the cardiovascular and cerebrovaseular events after drag administration （P〉0.05）. 1 case of gingival bleeding and 1 case of nasal bleeding were observed in the experimental group, with the total bleeding rate of 5.0%. 2 cases of gingival bleeding and 1 case of nasal bleeding were observed in the control group, with the total bleeding rate of 7.5%. There was no statistically significant difference in the total bleeding rate after drug administra- tion between the two groups（P〉0.05）. Conclusion The application of new oral anticoagulant of rivaroxaban tablets fn acute coronary syndrome is effective and

关 键 词：新型口服抗凝药 利伐沙班片 急性冠状动脉综合征 心脑血管事件 出血 

分 类 号：R541.4[医药卫生—心血管疾病]